Quanterix Invests in ImmunArray, Gains Access to Brain Injury Biomarker Portfolio | GenomeWeb

NEW YORK (GenomeWeb) – Quanterix today announced a strategic investment in ImmunArray, a move that could strengthen each company's efforts in addressing neurodegenerative disease diagnostics.

Under the terms of the agreement, Lexington, Massachusetts-based Quanterix will gain access to ImmunArray's biomarker portfolio for traumatic brain injury and add select biomarkers to its multiplex panel for neurology research. ImmunArray, based in both Israel and Virginia, will in turn gain access to Quantertix's Simoa single-molecule array technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.